Pharmacogenomics
The main pharmacogenes, the drugs involved, their recommendation level (CPIC, RNPGx) and evidence level (PharmGKB/ClinPGx). Each gene links to its page and the related Geno'X bibliographic watch.
clopidogrel, voriconazole, antidepressants (citalopram, escitalopram, sertraline, amitriptyline), proton-pump inhibitors
CPIC level A · RNPGx advised (antidepressants)
codeine and tramadol (opioids), tamoxifen, tricyclic antidepressants, SSRIs (paroxetine, fluvoxamine), atomoxetine, ondansetron
CPIC level A · RNPGx advised (antidepressants)
fluoropyrimidines: 5-fluorouracil, capecitabine, tegafur
CPIC level A · RNPGx "essential" (DPD deficiency screening)
tacrolimus
CPIC level A
abacavir (*57:01), carbamazepine / oxcarbazepine / phenytoin (*15:02), allopurinol (*58:01)
CPIC level A · RNPGx essential (abacavir)
thiopurines: azathioprine, 6-mercaptopurine, 6-thioguanine
CPIC level A
irinotecan; atazanavir
Irinotecan: RNPGx "essential", FDA/DPWG (no dedicated CPIC guideline). Atazanavir: CPIC level A.
warfarin, NSAIDs, phenytoin, fluvastatin
CPIC level A
statins (notably simvastatin) — myopathy risk
CPIC level A
thiopurines: azathioprine, 6-mercaptopurine, 6-thioguanine
CPIC level A · RNPGx "essential"
warfarin and vitamin-K antagonists
CPIC level A (with CYP2C9)
clozapine, caffeine
Limited / emerging evidence
isoniazid, hydralazine, sulfonamides
Emerging evidence
many substrates (immunosuppressants, statins, calcium-channel blockers)
No dedicated CPIC guideline
Level A = supported prescribing recommendation (source shown per row). PharmGKB 1A = pair backed by a CPIC or medical-society guideline. Indicative, non-exhaustive list — refer to current guidelines.